Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1972 3
1973 3
1974 1
1975 3
1976 3
1977 1
1978 1
1981 1
1985 1
1988 1
1990 1
1992 5
1995 1
1996 1
1997 1
1998 4
1999 2
2000 8
2001 7
2002 4
2003 6
2004 14
2005 25
2006 22
2007 12
2008 9
2009 20
2010 22
2011 19
2012 27
2013 20
2014 26
2015 19
2016 25
2017 35
2018 32
2019 51
2020 51
2021 46
2022 57
2023 46
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

572 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.
Tanaka K, Yu HA, Yang S, Han S, Selcuklu SD, Kim K, Ramani S, Ganesan YT, Moyer A, Sinha S, Xie Y, Ishizawa K, Osmanbeyoglu HU, Lyu Y, Roper N, Guha U, Rudin CM, Kris MG, Hsieh JJ, Cheng EH. Tanaka K, et al. Among authors: ishizawa k. Cancer Cell. 2021 Sep 13;39(9):1245-1261.e6. doi: 10.1016/j.ccell.2021.07.006. Epub 2021 Aug 12. Cancer Cell. 2021. PMID: 34388376 Free PMC article.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: ishizawa k. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. Cancer Sci. 2023. PMID: 37921363 Free PMC article.
[Overview].
Ishizawa K. Ishizawa K. Rinsho Ketsueki. 2022;63(6):618. doi: 10.11406/rinketsu.63.618. Rinsho Ketsueki. 2022. PMID: 35831196 Japanese. No abstract available.
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.
Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Yoshioka T, Izawa-Ishizawa Y, Yanagawa H, Tasaki Y, Ishizawa K. Chuma M, et al. Among authors: ishizawa k. Clin Infect Dis. 2022 Oct 12;75(8):1416-1422. doi: 10.1093/cid/ciac128. Clin Infect Dis. 2022. PMID: 35262686 Free PMC article.
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: ishizawa k. Haematologica. 2023 Mar 1;108(3):811-821. doi: 10.3324/haematol.2022.280996. Haematologica. 2023. PMID: 36200417 Free PMC article.
A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H. Terui Y, et al. Among authors: ishizawa k. Cancer Sci. 2021 Jul;112(7):2845-2854. doi: 10.1111/cas.14937. Epub 2021 Jun 4. Cancer Sci. 2021. PMID: 33942442 Free PMC article. Clinical Trial.
Iron accumulation causes impaired myogenesis correlated with MAPK signaling pathway inhibition by oxidative stress.
Ikeda Y, Satoh A, Horinouchi Y, Hamano H, Watanabe H, Imao M, Imanishi M, Zamami Y, Takechi K, Izawa-Ishizawa Y, Miyamoto L, Hirayama T, Nagasawa H, Ishizawa K, Aihara KI, Tsuchiya K, Tamaki T. Ikeda Y, et al. Among authors: ishizawa k. FASEB J. 2019 Aug;33(8):9551-9564. doi: 10.1096/fj.201802724RR. Epub 2019 May 30. FASEB J. 2019. PMID: 31145863
Age-Related Changes in Astigmatism and Potential Causes.
Namba H, Sugano A, Murakami T, Utsunomiya H, Nishitsuka K, Ishizawa K, Kayama T, Yamashita H. Namba H, et al. Among authors: ishizawa k. Cornea. 2020 Nov;39 Suppl 1:S34-S38. doi: 10.1097/ICO.0000000000002507. Cornea. 2020. PMID: 33038156 Review.
[Burkitt lymphoma: BL].
Ishizawa K. Ishizawa K. Rinsho Ketsueki. 2019;60(3):243-244. doi: 10.11406/rinketsu.60.243. Rinsho Ketsueki. 2019. PMID: 31068531 Japanese. No abstract available.
572 results